FDA okays start of BrainStorm stem cell trial in ALS patients

Reuters: BrainStorm Cell Therapeutics said the U.S. Food and Drug Administration approved the start of a mid-stage clinical trial of its adult stem cell treatment for patients with amyotrophic lateral sclerosis (ALS).

Read article